Loading...
Although adjuvant endocrine therapy has clearly been shown to reduce the risk for recurrence of estrogen receptor–positive, early-stage breast cancer, the rate of treatment noncompliance or nonadherence among patients is estimated to be greater than 50%. To determine the impact of discontinuing and then restarting endocrine therapy, investigators conducted a population-based cohort study by linking data from Swedish breast cancer and prescribed drug registers and patient-reported questionnaires.
Women who received a diagnosis of breast cancer between 2005 and 2008 and had received a prescription for adjuvant tamoxifen or an aromatase inhibitor were followed until 2015. Restarting treatment was defined as filling at least two prescriptions af…